A Phase 1b/2 Open-Label, Multicenter Study of RMC-9805 with or without RMC-6236, in Combination with Other Anticancer Agents, in Patients with RAS G12D-Mutated Non-Small Cell Lung Cancer (NSCLC) – Subprotocol C

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521147-21-00

Acronym

RMC-LUNG-101C

Enrollment

130

Registered

2025-10-06

Start date

2025-10-08

Completion date

Unknown

Last updated

2026-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Brief summary

1. Incidence of DLTs; Part 1 and Part 2 (Cohort C3 safety lead-in only)., 2. Incidence of TEAEs, TRAEs, SAEs, and clinically significant changes in vital signs, laboratory test values, and ECGs.

Detailed description

1. Concentrations of RMC-9805 and RMC-6236 (if applicable) in blood over time., 2. ORR and DOR as per RECIST v1.1

Interventions

DRUGPEMBROLIZUMAB

DRUGDARAXONRASIB (RMC-6236)

DRUGCARBOPLATIN

DRUGPEMETREXED

DRUGCISPLATIN

DRUGRMC-9805

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
1. Incidence of DLTs; Part 1 and Part 2 (Cohort C3 safety lead-in only)., 2. Incidence of TEAEs, TRAEs, SAEs, and clinically significant changes in vital signs, laboratory test values, and ECGs.	—

Secondary

Measure	Time frame
1. Concentrations of RMC-9805 and RMC-6236 (if applicable) in blood over time., 2. ORR and DOR as per RECIST v1.1	—

Countries

Austria, Czechia, Denmark, France, Germany, Greece, Italy, Netherlands, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026